---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-245815"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2023-09-28T23:59:59+00:00"
generated_at: "2026-06-10T07:43:05.405825+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunovant Prices $280M Public Offering; Roivant Commits $170M Private Placement

## Summary
- Public offering of 7,370,000 shares at $38.00/share; gross proceeds ~$280.1M.
- Roivant Sciences, majority stockholder, to purchase 4,473,684 shares at same price; proceeds ~$170M.
- Combined gross proceeds ~$450M before expenses; expected closing October 2, 2023.
- Underwriters granted 30-day option to buy up to 1,105,500 additional shares.
- Private placement exempt from registration under Section 4(a)(2) of Securities Act.

## SEC filing metadata
- accession: 0001193125-23-245815
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2023-09-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000119312523245815/0001193125-23-245815-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000119312523245815/d555888d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-245815
- JSON: https://secwatch.observer/filing/0001193125-23-245815.json
- Plain text: https://secwatch.observer/filing/0001193125-23-245815.txt

## Key facts
- Material Agreements
  Immunovant, Inc. entered into Purchase Agreement with Roivant Sciences, Ltd. valued at approximately $170,000,000 (effective 2023-09-26).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Roivant Sciences, Ltd.
  - Value: approximately $170,000,000
  - Effective: 2023-09-26
  source text: On September 26, 2023, the Company entered into a common stock purchase agreement (the “Purchase Agreement”) with Roivant Sciences, Ltd. (“RSL”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000119312523245815/0001193125-23-245815-index.htm
- Material Agreements
  Immunovant, Inc. entered into Underwriting Agreement with Leerink Partners LLC, Piper Sandler & Co., Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives of the underwriters valued at approximately $280,060,000 (effective 2023-09-27).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Leerink Partners LLC, Piper Sandler & Co., Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives of the underwriters
  - Value: approximately $280,060,000
  - Effective: 2023-09-27
  source text: On September 27, 2023, Immunovant, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Piper Sandler & Co., Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives (the “Representatives”) of the underwriters listed on Schedule A thereto, relating to the issuance and sale in an underwritten public offering (the “Public Offering”) by the Company of 7,370,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a public offering price of $38.00 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000119312523245815/0001193125-23-245815-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.